RecruitingNot ApplicableNCT05642858
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
Sponsor
University of California, San Francisco
Enrollment
260 participants
Start Date
Mar 12, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The overall objective is to evaluate the efficacy of educational text messages to reduce cardiovascular risk among persons living with HIV (PLWH).
Eligibility
Min Age: 40 Years
Plain Language Summary
Simplified for easier understanding
This study is testing whether a text message education program about heart health can improve knowledge and motivation to reduce cardiovascular risk in people living with HIV who are 40 years and older.
**You may be eligible if...**
- You are HIV-positive
- You are at least 40 years old
- You speak English
- You own a smartphone
**You may NOT be eligible if...**
- You already have diagnosed heart disease (atherosclerotic cardiovascular disease)
- You are pregnant
- You are unwilling or unable to provide informed consent
- You do not have a smartphone
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BEHAVIORALDigital Educational Messaging
Education via mobile phone text messages for up to 6 months.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05642858
Related Trials
Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV
NCT000012812 locations
Viral Load in Blood and Lymph Tissues in People Living With HIV
NCT000013161 location
Diabetes and Heart Disease Risk in Blacks
NCT000018531 location
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
NCT000065181 location
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
NCT054704911 location